Bank of America Merrill Lynch is out with its report today on Regeneron Pharmaceuticals REGN, maintaining Neutral.
In its report, Bank of America Merrill Lynch writes, "We rate REGN shares Neutral. Our DCF-derived PO of $58 is based on risk-adjusted revenue projections of the key pipeline products (Eylea, rilonacept, aflibercept, antibody program)."
At the time of posting, shares of REGN were trading pre-market at $55.70, down 0.39% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in